IKTInhibikase Therapeutics, Inc.同业对比
Inhibikase Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IKT本股 | $208M#8 | — | 1.4x#7 | — | -100.0%#8 | -75.4%#13 | — | -31.5%#5 | — | — | -8.0%#5 | — |
| OCGN | $258M#1 | — | — | 58.4x#9 | 8.8%#3 | -25.9%#7 | -1425.7%#7 | — | — | — | — | — |
| LXEO | $257M#2 | — | 1.1x#5 | 393.3x#10 | — | -1.7%#4 | -16706.0%#10 | -42.5%#9 | — | — | — | — |
| FATE | $245M#3 | — | 1.6x#8 | 36.9x#7 | -51.2%#6 | 26.8%#2 | -2222.4%#9 | -88.8%#12 | -102.3%#2 | — | — | — |
| CABA | $242M#4 | — | 1.2x#6 | — | — | -44.9%#12 | — | -79.7%#10 | — | — | — | — |
| ALEC | $230M#5 | — | — | 10.9x#5 | -79.1%#7 | -20.2%#6 | -741.3%#6 | — | — | — | 42.1%#1 | — |
| PALI | $216M#6 | 1.9x#1 | 1.8x#9 | — | — | -16.2%#5 | — | -13.8%#2 | — | — | — | — |
| PLX | $209M#7 | 11.3x#2 | 2.9x#10 | 4.0x#3 | -1.2%#4 | -325.2%#15 | -10.4%#1 | -9.2%#1 | -12.3%#1 | 3#1 | 9.3%#3 | — |
| ARTV | $206M#9 | — | 0.6x#1 | — | -100.0%#8 | -28.3%#8 | — | -24.1%#3 | — | — | 12.0%#2 | — |
| DTIL | $194M#10 | 21.7x#3 | 3.7x#12 | 5.7x#4 | -50.1%#5 | -738.0%#16 | -152.2%#3 | -88.3%#11 | — | — | -6.1%#4 | — |
| ACOG | $180M#11 | — | 3.4x#11 | 17.6x#6 | — | -39.8%#11 | -221.7%#5 | -39.0%#7 | — | — | — | — |
| IVVD | $172M#12 | — | 1.0x#4 | 3.2x#2 | 110.5%#1 | 69.1%#1 | -104.0%#2 | -29.0%#4 | — | — | -63.5%#6 | — |
| LIMN | $169M#13 | — | 563.0x#13 | — | — | -187.8%#14 | — | -3395.2%#13 | -170.3%#3 | — | — | — |
| STRO | $157M#14 | — | — | 1.5x#1 | 65.2%#2 | 15.9%#3 | -154.5%#4 | — | — | — | — | — |
| TARA | $144M#15 | — | 0.9x#3 | 48.7x#8 | — | -28.7%#9 | -2189.6%#8 | -35.6%#6 | — | — | — | — |
| CMPX | $138M#16 | — | 0.8x#2 | — | -100.0%#8 | -34.7%#10 | — | -40.0%#8 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议